These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16011271)

  • 21. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations.
    Guchardi R; Frei M; John E; Kaerger JS
    Int J Pharm; 2008 Feb; 348(1-2):10-7. PubMed ID: 17689898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Jun; 43(6):980-988. PubMed ID: 28122460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate.
    Lau M; Young PM; Traini D
    AAPS PharmSciTech; 2017 Aug; 18(6):2248-2259. PubMed ID: 28070849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate.
    Kumon M; Machida S; Suzuki M; Kusai A; Yonemochi E; Terada K
    Chem Pharm Bull (Tokyo); 2008 May; 56(5):617-25. PubMed ID: 18451547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lactose characteristics and the generation of the aerosol.
    Pilcer G; Wauthoz N; Amighi K
    Adv Drug Deliv Rev; 2012 Mar; 64(3):233-56. PubMed ID: 21616107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of carrier surface fines on dry powder inhalation formulations.
    Boshhiha AM; Urbanetz NA
    Drug Dev Ind Pharm; 2009 Aug; 35(8):904-16. PubMed ID: 19466888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preparation and pharmaceutical properties of salcatonin dry powder inhalations].
    Xiong LJ; Zhu JB
    Yao Xue Xue Bao; 2003 Mar; 38(3):218-22. PubMed ID: 12830721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed.
    Iida K; Todo H; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2005 Apr; 53(4):431-4. PubMed ID: 15802846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
    Young PM; Chan HK; Chiou H; Edge S; Tee TH; Traini D
    J Pharm Sci; 2007 May; 96(5):1331-41. PubMed ID: 17455362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer.
    Ferrari F; Cocconi D; Bettini R; Giordano F; Santi P; Tobyn M; Price R; Young P; Caramella C; Colombo P
    AAPS PharmSciTech; 2004 Sep; 5(4):e60. PubMed ID: 15760057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Recent progress of dry powder inhalation of proteins and peptides].
    Zhou JY; Zhang L; Mao SR
    Yao Xue Xue Bao; 2015 Jul; 50(7):814-23. PubMed ID: 26552141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics.
    Hickey AJ; Mansour HM; Telko MJ; Xu Z; Smyth HD; Mulder T; McLean R; Langridge J; Papadopoulos D
    J Pharm Sci; 2007 May; 96(5):1282-301. PubMed ID: 17455324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
    Chan LW; Lim LT; Heng PW
    J Pharm Sci; 2003 May; 92(5):975-84. PubMed ID: 12712417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of inhalable dry powder formulation of basic fibroblast growth factor.
    Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
    Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.